Compounds of formula (I) ##STR00001## wherein R.sup.1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted, and R.sup.2 to R.sup.4 are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type I and type II diabetes mellitus, arthritis, obesity, allograft transplantation and calcitonin-induced osteoporosis using these compounds.

Boehringer Ingelheim Pharma GmbH &amp; Co. KG

Xanthine derivatives, their preparation and their use in pharmaceutical compositions

Compounds of formula (I) ##STR00001## wherein R.sup.1 is a phenylcarbonylmethyl group wherein the phenyl moiety is substituted by R.sup.10 and R.sup.11 and R.sup.2 to R.sup.4 and R.sup.10 and R.sup.1l are defined as in the claims, or the prodrugs or salts thereof, particularly the physiologically acceptable salts thereof, pharmaceutical compositions containing these compounds, and methods of treating type II diabetes mellitus and obesity using these compounds.

Boehringer Ingelheim International GmbH

Xanthine derivates, their preparation and their use in pharmaceutical compositions

To provide a lipolysis agent, a slimming agent, and a cellulite-ameliorating agent, which stimulate decomposition of fat accumulated in the adipose tissue, to thereby exhibit body-slimming effect and which is effective for inhibition or prevention of obesity and amelioration of prone to obesity. The lipolysis stimulator of the invention contains, as effective ingredients, a plant Huang Hua Cai or an extract thereof, and a xanthine derivative.

Kao Corporation

Lipolysis stimulator

A composition comprising (a) and (b), and a food or drink or a medicine comprising the composition, wherein (a) is at least a kind of polyphenols selected from the group consisting of a polyphenol containing 15 mass % or more of proanthocyanidin having a polymerization degree of 1 to 3, hesperidin, a hesperidin derivative, and hesperetin; and (b) is at least a kind of xanthine derivatives, the mass ratio of (a):(b) in the composition being 1:(0.001 to 5), are useful for the prevention, amelioration, or treatment of metabolic syndrome, disorders of lipid metabolism (for example, fatty liver, hyperlipidemia), obesity (for example, visceral fat accumulation, subcutaneous fat accumulation), or the like.

xanthine/obezitate

Xanthine derivatives, their preparation and their use in pharmaceutical compositions

Xanthine derivates, their preparation and their use in pharmaceutical compositions

Lipolysis stimulator

Composition for prevention, amelioration or treatment of metabolic syndrome

Cea mai completă bază de date cu plante medicinale susținută de știință